Table 3.
Summary of current clinical trials of intravenous nanoparticles: (i) for applications other than cancer, iron‐replacement, or imaging, (ii) that are targeted to specific tissues, and (iii) that are stimuli‐responsive
| Name (company) | Particle type/drug | Investigated application/indication | ClinicalTrials.gov identifier (phase) |
|---|---|---|---|
| Applications other than cancer, iron‐replacement, or imaging | |||
| ND‐L02‐s0201 (Nitto Denko) | siRNA lipid nanoparticle conjugated to Vitamin A | Hepatic fibrosis | NCT02227459 (Ph I) |
| ARB‐001467 TKB‐HBV (Arbutus Biopharma) | Lipid particle containing three RNAi therapeutics that target three sites on the HBV genome | Hepatitis B | NCT02631096 (Ph II) |
| Patisiran ALN‐TTR02 (Alnylam Pharmaceuticals) | Lipid nanoparticle RNAi for the knockdown of disease‐causing TTR protein | Transthyretin (TTR)‐mediated amyloidosis |
NCT02510261 (Ph III) NCT01961921 (Ph II) NCT01960348 (Ph III) |
| CAL02 (Combioxin SA) | Sphingomyelin and cholesterol liposomes for toxin neutralization | Pneumonia | NCT02583373 (Ph I) |
| Nanocort (Enceladus in collaboration with Sun Pharma Global) | Liposomal Prednisolone (PEGylated) | Rheumatoid arthritis and hemodialysis fistula maturation |
NCT02495662 (Ph II) NCT02534896 (Ph III) |
| RGI‐2001 (Regimmune) | Liposomal formulation of α‐GalCer | Mitigating graft versus host disease following stem cell transplant | NCT01379209 (Ph I/II) |
| RadProtect (Original BioMedicals) |
PEG, iron, and amifostine micelle Transferrin‐mediated chelation for amifostine release |
Dose escalation and safety for acute radiation syndrome | NCT02587442 (Ph I) |
| Targeted nanoparticles | |||
| ND‐L02‐s0201 (Nitto Denko) | siRNA lipid nanoparticle conjugated to Vitamin A | Hepatic fibrosis | NCT02227459 (Ph I) |
| BIND‐014 (BIND Therapeutics) | PSMA targeted (via ACUPA) docetaxel PEG‐PLGA or PLA‐PEG particle | Prostate, metastatic, nonsmall cell lung, cervical, head and neck, or KRAS positive lung cancers |
NCT02479178 (Ph II) NCT02283320 (Ph II) NCT01812746 (Ph II) NCT01792479 (Ph II) NCT01300533 (Ph I) |
| MM‐302 (Merrimack Pharmaceuticals) | HER2‐targeted liposomal doxorubicin (PEGylated) | Breast cancer |
NCT01304797 (Ph I) NCT02213744 (Ph II/III) |
| TargomiRs (EnGeneIC) | Anti‐EGFR bispecific antibody minicells (bacteria derived nanoparticles) with a miR‐16 based microRNA payload | Mesothelioma and nonsmall cell lung cancer | NCT02369198 (Ph I) |
| SGT‐53 (SynerGene Therapeutics) | Cationic liposome with anti‐transferrin receptor antibody, encapsulating Wildtype p53 sequence | Glioblastoma, solid tumors, or pancreatic cancer |
NCT02354547 (Ph I) NCT00470613 (Ph I) NCT02354547 (Ph I) NCT02340156 (Ph II) |
| SGT‐94 (SynerGene Therapeutics) | RB94 plasmid DNA in a liposome with anti‐transferrin receptor antibody | Solid tumors | NCT01517464 (Ph I) |
| Cornell Dots | Silica nanoparticles with a NIR fluorophore, PEG coating, and a 124I radiolabeled cRGDY targeting peptide | Imaging of melanoma and malignant brain tumors | NCT01266096 (Not Provided) |
| Stimuli responsive (nonimaging applications) | |||
| ThermoDox® (Celsion) | Lyso‐thermosensitive liposomal doxorubicin |
Temperature‐triggered doxorubicin release: Breast cancer recurrence at chest wall (microwave hypothermia) Hepatocellular carcinoma (radiofrequency ablation) Liver tumors (mild hypothermia) Refractory solid tumors (magnetic resonance high intensity focused ultrasound) |
NCT00826085 (Ph I/II) NCT02112656 (Ph III) NCT02181075 (Ph I) NCT02536183 (Ph I) |
| RadProtect (Original BioMedicals) |
PEG, iron, and amifostine micelle Transferrin‐mediated chelation for amifostine release |
Dose escalation and safety for acute radiation syndrome | NCT02587442 (Ph I) |
| LiPlaCis (LiPlasome Pharma) | Liposomal formulated cisplatin with specific degradation‐controlled drug release via phospholipase A2 (PLA2) | Advanced or refractory tumors | NCT01861496 (Ph I) |
| AuroLase (Nanospectra Biosciences) | PEG‐coated silica‐gold nanoshells for near infrared light facilitated thermal ablation | Thermal ablation of solid primary and/or metastatic lung tumors | NCT01679470 (Not Provided) |
| NBTXR3 PEP503 (Nanobiotix) | Hafnium oxide nanoparticles stimulated with external radiation to enhance tumor cell death via electron production | Locally advanced squamous cell carcinoma | NCT01946867 (Ph I) |
| Magnablate | Iron nanoparticles | Thermal ablation for prostate cancer | NCT02033447 (Ph 0) |